Characteristics of U.S. adults taking prescription antipsychotic medications, National Health and Nutrition Examination Survey 2013–2018

Abstract

Background Global 12-month psychosis prevalence is estimated at roughly 0.4%, although prevalence of antipsychotic use in the U.S. is estimated at roughly 1.7%. Antipsychotics are frequently prescribed for off label uses, but have also been shown to carry risk factors for certain comorbid conditions and with other prescription medications. The study aims to describe the socio-demographic and health characteristics of U.S. adults taking prescription antipsychotic medications, and to better understand the association of antipsychotic medications and comorbid chronic diseases. Methods The study pools 2013–2018 data from the National Health and Nutrition Examination Survey (NHANES), a nationally representative cross-sectional survey of non-institutionalized U.S. residents (n = 17,691). Survey staff record prescription medications taken within the past 30 days for each respondent, from which typical and atypical antipsychotic medications were identified. Results Prevalence of antipsychotic use among U.S. adults was 1.6% (n = 320). Over 90% of individuals taking antipsychotics reported having health insurance and a usual place for care, significantly more than their counterparts not taking antipsychotics. Further, those taking antipsychotics reported higher prevalence of comorbid chronic diseases and took an average of 2.3 prescription medications more than individuals not taking antipsychotics. Individuals taking antipsychotics were more likely to sleep 9 or more hours per night, be a current smoker, and have a body mass index greater than 30 kg/m2. Conclusions U.S. adults who take antipsychotic medications report more consistent health care access and higher prevalence of comorbid chronic diseases compared to those not taking antipsychotics. The higher comorbidity prevalence and number of total prescriptions highlight the need for careful assessment and monitoring of existing comorbidities and potential drug-drug interactions among adults taking antipsychotics in the U.S.

Are Amphetamines Associated with Adverse Cardiovascular Events Among Elderly Individuals?

“…However, the potential impact of QT segment prolongation was not captured with these data. A recent study using the National Health and Nutrition Examination Survey dataset found that the use of antipsychotics for ADHD was too rare to include in their threshold for analysis 24 (which suggests this variable is unlikely to influence the inferences of our study). However, we believe assessing the relationship between QT-prolonging medications, amphetamines, and cardiovascular events in older adults is worth evaluating.…”

Targeting neurotransmitter-mediated inflammatory mechanisms of psychiatric drugs to mitigate the double burden of multimorbidity and polypharmacy

“…This creates a number of issues as these are the patients that are seen increasingly in clinical practice; and who are most likely to be affected by adverse drug interactions. In particular, these issues affect a large proportion of individuals suffering from psychiatric disorders, who have an elevated risk of multimorbidity as well as a shorter life expectancy with an increased occurrence of fatal intoxication and polypharmacy ( Reuss et al., 2021 ; Kukreja et al., 2013 ; Dennis et al., 2020 ). This double burden of multimorbidity and prescription drugs is an increasing problem in the growing aging population ( Nobili et al., 2011 ; de Lima et al., 2020 ; Ersoy and Engin, 2018 ).…”

Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies

“…They can be treated with a combination of different drugs, such as antipsychotics, antidepressants, mood stabilizers, and anxiolytic drugs. According to the National Health and Nutrition Examination Survey (NHANES) data collected between 2013 and 2018, which included 17,691 U.S. residents, the estimated prevalence of antipsychotic drug use was 1.6% ( Dennis et al, 2020 ). In 2020, antipsychotic drugs were prescribed more than 5 million times ( Dennis et al, 2020 ).…”